Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
CCOP - Kansas City
mi
from
Prairie Village, KA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
CCOP - Kansas City
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Cooper CyberKnife Center
mi
from
Mount Laurel, NJ
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Cooper CyberKnife Center
mi
from
Mount Laurel, NJ
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Princess Margaret Hospital
mi
from
Toronto,
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated:  3/22/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated: 3/22/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated:  3/22/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated: 3/22/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated:  3/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Status: Enrolling
Updated: 3/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
ATTN-Research Pharmacist
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
ATTN-Research Pharmacist
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Connecticut Multispecialty Group
mi
from
Enfield, CT
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Connecticut Multispecialty Group
mi
from
Enfield, CT
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Florida Cancer Specialists
mi
from
Sarasota, FL
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic
mi
from
Corinth, MS
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic
mi
from
Corinth, MS
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic, PC
mi
from
Southaven, MS
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic, PC
mi
from
Southaven, MS
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center - IDS Pharmacy
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center - IDS Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center - OPD Pharmacy
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center - OPD Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic, PC
mi
from
Memphis, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
West Clinic
mi
from
Germantown, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
West Clinic
mi
from
Germantown, TN
Click here to add this to my saved trials
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)
Status: Enrolling
Updated:  3/22/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)
Status: Enrolling
Updated: 3/22/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated:  3/22/2018
Tom Baker Cancer Centre
mi
from
Calgary,
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated: 3/22/2018
Tom Baker Cancer Centre
mi
from
Calgary,
Click here to add this to my saved trials
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers
Status: Enrolling
Updated:  3/22/2018
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers
Status: Enrolling
Updated: 3/22/2018
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation
Status: Enrolling
Updated:  3/23/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation
Status: Enrolling
Updated: 3/23/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Providence VA Medical Center, Providence, RI
mi
from
Providence, RI
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA San Diego Healthcare System, San Diego, CA
mi
from
San Diego, CA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Eastern Colorado Health Care System, Denver, CO
mi
from
Denver, CO
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Bay Pines VA Healthcare System, Pay Pines, FL
mi
from
Bay Pines, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated:  3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Status: Enrolling
Updated: 3/23/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials